Altria (MO) Q3 2024 Earnings Call Transcript

Altria reported Q3 adjusted diluted EPS up 7.8% and reaffirmed full-year guidance of $5.07 to $5.15, while smokable segment OCI rose 7.1% and margins expanded to 63.1%. Growth in NJOY and on! remained strong, with NJOY consumables up more than 15%, device shipments nearly tripling, and on! cans up 46%, though cigarette volumes declined 8.6% and the company flagged ongoing illicit-product and inflation pressures. Shareholder returns remained substantial, with $1.7B in dividends and $680M of buybacks, while litigation over NJOY patent disputes and regulatory scrutiny remain key risks.

Analysis

The core setup is not the headline earnings beat; it is the widening gap between cash generation and terminal-category risk. MO is still extracting pricing power from combustibles while funding smoke-free adjacencies, but the composition of growth is deteriorating underneath: premium share is holding while overall category share leaks to lower-price and illicit channels. That is usually late-cycle behavior in a regulated consumer franchise — margins can stay elevated for several quarters, but unit elasticity eventually shows up in a more persistent share bleed than investors expect.

The more important second-order effect is that illicit substitution is no longer just a regulatory talking point; it is a direct operating variable for every legal nicotine franchise. If enforcement remains lax, Altria’s smoke-free investments may keep printing share gains in absolute terms, but the addressable market for authorized products stays artificially capped, which delays the inflection where NJOY and on! become self-funding growth businesses. Conversely, any real enforcement step would likely benefit MO disproportionately versus smaller vapor and pouch challengers that lack the distribution and legal firepower to survive a cleanup.

The litigation overhang is the clearest near-term catalyst, and it is binary over a 2-6 month horizon. The market is probably underpricing the possibility that NJOY can keep a commercial footprint even in an adverse ITC outcome via product tweaks and import workarounds, but the path to that outcome looks messy and could cause a temporary shipment air-pocket. That makes the stock less interesting as a clean growth story and more interesting as a cash-yield carry trade with event-driven optionality.

Consensus is likely missing how much of the current valuation rests on the assumption that smoke-free growth will compensate for combustible decay without a policy reset. If that reset does not arrive, the business can still compound cash for a while, but the multiple should remain capped by structural volume erosion and legal uncertainty. The paradox is that the most bullish long-term outcome for MO may require near-term regulatory intervention that also creates headline volatility and an entry point.

Key Decisions for Investors

• Long MO vs short PM for 3-6 months: MO has more visible capital return support and more direct upside from any U.S. enforcement cleanup in vapor/pouches; downside is that it is more exposed to U.S. combustibles deterioration, so size modestly and hedge with sector exposure.
• Sell short-dated MO puts into litigation/event volatility (30-60 DTE): monetize elevated implied volatility around the late-December ITC decision; risk is a sudden upside gap if the market interprets an adverse ruling as containable.
• Pair trade long MO / short a basket of smaller nicotine-exposure names with less regulatory leverage: if enforcement improves, MO’s scale and lobbying reach should outperform the smaller players; if enforcement stays weak, the basket should underperform but MO’s cash flow cushions the trade.
• If MO sells off 5-8% on any NJOY legal headline, buy for a 6-12 month horizon: the market is likely to over-discount a permanent disruption, while the company’s dividend and buyback support should limit sustained downside.
• Avoid chasing the stock after strong quarters; use pullbacks, because the next leg of upside likely needs a policy or litigation catalyst rather than just another cash-flow beat.